Inventor
YERRAMREDDY VENKATAKRISHNAREDDY
IN9 patents
Patents
9 patentsUS9359315B2Jun 7, 2016
Substituted 2,3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis
ARRIEN PHARMACEUTICALS LLC4 citations82
US9951062B2Apr 24, 2018
Substituted 1 H-pyrrolo [2, 3-b] pyridine and 1 H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
ARRIEN PHARMACEUTICALS LLC3 citations69
US9890153B2Feb 13, 2018
Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
ARRIEN PHARMACEUTICALS LLC4 citations69
US9260426B2Feb 16, 2016
Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
ARRIEN PHARMACEUTICALS LLC4 citations69
US9206188B2Dec 8, 2015
Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
ARRIEN PHARMACEUTICALS LLC5 citations68
US10682358B2Jun 16, 2020
Substituted 2, 3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis
ARRIEN PHARMACEUTICALS LLC0 citations50
US10172866B2Jan 8, 2019
Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis
ARRIEN PHARMACEUTICALS LLC0 citations50
US9446047B2Sep 20, 2016
Substituted 2,3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis
ARRIEN PHARMACEUTICALS LLC0 citations50
US9834551B2Dec 5, 2017
Substituted pyrrolo[2,3-b]pyrazines and substituted pyrazolo[3,4-b]pyridines as ITK and JAK kinase inhibitors
ARRIEN PHARMACEUTICALS LLC0 citations48